Treatment of lower urinary tract symptoms: Agents for intraprostatic injection

References

• Ala-Opas MY, Aitola PT, Metsola TE. Evaluation of immediate and late results of transurethral resection of the prostate. Scand J Urol Nephrol 1993;27:235–9.
   PubMed Web of Science ®Google Scholar
• Ahlstrand C, Carlsson P, Jönsson B. An estimate of the life-time cost of surgical treatment of patients with benign prostatic hyperplasia in Sweden. Scand J Urol Nephrol 1996;30:37–43.
   PubMed Web of Science ®Google Scholar
• Johansen TE, Istad JA. Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway. Scand J Urol Nephrol 2007;41:124–31.
   PubMedGoogle Scholar
• Plante MK, Folsom JB, Zvara P. Prostatic tissue ablation by injection: a literature review. J Urol 2004;172:20–6.
   PubMedGoogle Scholar
• Saemi AM, Plante MK. Injectables in the prostate. Curr Opin Urol 2008;18:28–33.
   PubMed Web of Science ®Google Scholar
• Chapple C. Intraprostatic injection therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Eur Urol 2011;59:755–6.
   PubMedGoogle Scholar
• Lu-Yao GL, Barry MJ, Chang CH, Wasson JH, Wennberg JE. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology 1994;44:692–8.
   PubMedGoogle Scholar
• McConnell JD. Benign prostatic hyperplasia. J Urol 1994;152:459–60.
   PubMedGoogle Scholar
• Roosen A, Chapple CR, Dmochowski RR, Fowler CJ, Gratzke C, Roehrborn CG, A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol 2009;56:810–19.
   PubMed Web of Science ®Google Scholar
• Chughtai B, Lee R, Te A, Kaplan S. Inflammation and benign prostatic hyperplasia: clinical implications. Curr Urol Rep 2011;12:274–7.
   PubMedGoogle Scholar
• Macoska JA. Chemokines and BPH/LUTS. Differentiation 2011;82:253–60.
   PubMed Web of Science ®Google Scholar
• Danuser H, Springer JP, Katofiasc MA, Thor KB. Extrinsic innervation of the cat prostate gland: a combined tracing and immunohistochemical study. J Urol 1997;157:1018–24.
   PubMedGoogle Scholar
• Higgins JR, Gosling JA. Studies on the structure and intrinsic innervation of the normal human prostate. Prostate Suppl 1989;2:5–16.
   PubMedGoogle Scholar
• Hedlund P, Ekström P, Larsson B, Alm P, Andersson KE. Heme oxygenase and NO-synthase in the human prostate – relation to adrenergic, cholinergic and peptide-containing nerves. J Auton Nerv Syst 1997;63:115–26.
   PubMedGoogle Scholar
• Pennefather JN, Lau WA, Mitchelson F, Ventura S. The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. J Auton Pharmacol 2000;20:193–206.
   PubMedGoogle Scholar
• Chalfin SA, Bradley WE. The etiology of detrusor hyperreflexia in patients with infravesical obstruction. J Urol 1982;127:938–42.
   PubMedGoogle Scholar
• Plante MK, Gross AL, Kliment J, Kida M, Zvara P. Intraprostatic ethanol chemoablation via transurethral and transperineal injection. BJU Int 2003;91:94–8.
   PubMedGoogle Scholar
• Buchholz NN, Andrews HO, Plante MK. Transurethral ethanol ablation of prostate. J Endourol 2004;18:519–24.
   PubMedGoogle Scholar
• Grise P, Plante M, Palmer J, Martinez-Sagarra J, Hernandez C, Schettini M, Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur Urol 2004;46:496–501.
   PubMedGoogle Scholar
• Sakr M, Eid A, Shoukry M, Fayed A. Transurethral ethanol injection therapy of benign prostatic hyperplasia: four-year follow-up. Int J Urol 2009;16:196–201.
   PubMedGoogle Scholar
• El-Husseiny T, Buchholz N. Transurethral ethanol ablation of the prostate for symptomatic benign prostatic hyperplasia: long-term follow-up. J Endourol 2011;25:477–80.
   PubMedGoogle Scholar
• Goya N, Ishikawa N, Ito F, Kobayashi C, Tomizawa Y, Toma H. Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results. J Urol 2004;172:1017–20.
   PubMed Web of Science ®Google Scholar
• Plante MK, Marks LS, Anderson R, Amling C, Rukstalis D, Badlani G, Phase I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 2007;177:1030–5.
   PubMedGoogle Scholar
• Plante MK, Gross AL, Folsom JB, Zvara P. Diffusion properties of transurethral intraprostatic injection. BJU Int 2004;94:1384–8.
   PubMedGoogle Scholar
• Larson BT, Netto N, Huidobro C, de Lima ML, Matheus W, Acevedo C, Intraprostatic injection of alcohol gel for the treatment of benign prostatic hyperplasia: preliminary clinical results. Scientific World Journal 2006;6:2474–80.
   Google Scholar
• Oeconomou A, Madersbacher H. Botulinum neurotoxin A for benign prostatic hyperplasia. Curr Opin Urol 2010;20:28–36.
   PubMedGoogle Scholar
• Chartier-Kastler E, Mehnert U, Denys P, Giuliano F. Botulinum neurotoxin A for male lower urinary tract symptoms. Curr Opin Urol 2011;21:13–21.
   PubMed Web of Science ®Google Scholar
• Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA 2011;305:89–90.
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Yamamoto Y, Suzuki T, Oguma K, Nagai A. Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia: preliminary results with a newly purified neurotoxin. Acta Med Okayama 2012;66:291–7.
   PubMedGoogle Scholar
• Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003;62:259–64.
   PubMed Web of Science ®Google Scholar
• Kuo HC. Prostate botulinum A toxin injection – an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005;65:670–4.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005;66:775–9.
   PubMed Web of Science ®Google Scholar
• Silva J, Pinto R, Carvallho T, Coelho A, Avelino A, Dinis P, Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat. Eur Urol 2009;56:134–40.
   PubMed Web of Science ®Google Scholar
• Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. Botox-induced prostatic involution. Prostate 1998;37:44–50.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Huang CC, Kang HY, Chiang PH, Demiguel F, Yoshimura N, Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 2006;175:1158–63.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Tu CH, Huang CC, Lin HJ, Chiang PH, Yoshimura N, Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol 2006;6:12.
   PubMedGoogle Scholar
• Chuang YC, Yoshimura N, Huang CC, Wu M, Chiang PH, Chancellor MB. Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. J Urol 2008;180:742–8.
   PubMed Web of Science ®Google Scholar
• Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 2007;4:368–78.
   PubMedGoogle Scholar
• Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785–93.
   PubMed Web of Science ®Google Scholar
• Rapp DE, Turk KW, Bales GT, Cook SP. Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 2006;175:1138–42.
   PubMedGoogle Scholar
• Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 2007;120:2864–74.
   PubMed Web of Science ®Google Scholar
• Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 2008;101:366–70.
   PubMedGoogle Scholar
• Ikeda Y, Zabbarova IV, Birder LA, de Groat WC, McCarthy CJ, Hanna-Mitchell AT, Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. Eur Urol 2012;62:1157–64.
   PubMedGoogle Scholar
• Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 2006;98:1033–7.
   PubMed Web of Science ®Google Scholar
• Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P, Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol 2008;53:153–9.
   PubMed Web of Science ®Google Scholar
• Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 2009;73:90–4.
   PubMed Web of Science ®Google Scholar
• Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Oliveira R, Intraprostatic botulinum toxin type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol 2009;9:9.
   PubMedGoogle Scholar
• Kuo HC, Liu HT. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand J Urol Nephrol 2009;43:206–11.
   PubMed Web of Science ®Google Scholar
• Nikoobakht M, Daneshpajooh A, Ahmadi H, Namdari F, Rezaeidanesh M, Amini S, Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: initial experience with Dysport. Scand J Urol Nephrol 2010;44:151–7.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT, Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol 2011;186:965–70.
   PubMed Web of Science ®Google Scholar
• Arnouk R, Suzuki Bellucci CH, Stull RB, de Bessa Junior J, Malave CA, Gomes CM. Botulinum neurotoxin type a for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. ScientificWorldJournal 2012;2012:463574.
   PubMedGoogle Scholar
• de Kort LM, Kok ET, Jonges TN, Rosier PF, Bosch JL. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia. Urology 2012;80:889–93.
   PubMedGoogle Scholar
• Sacco E, Bientinesi R, Marangi F, Totaro A, D'Addessi A, Racioppi M, Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study. BJU Int 2012; doi: 10.1111/j.1464-410X.2012.11288.x. [Epub ahead of print].
   Google Scholar
• Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Silva C, Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int 2011;107:1950–4.
   PubMed Web of Science ®Google Scholar
• Shore N. NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2010;19:305–10.
   PubMed Web of Science ®Google Scholar
• Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 2007;99:376–85.
   PubMed Web of Science ®Google Scholar
• Singh R, Browning JL, Abi-Habib R, Wong K, Williams SA, Merchant R, Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anticancer Drugs 2007;18:809–16.
   PubMedGoogle Scholar
• Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2011;59:747–54.
   PubMed Web of Science ®Google Scholar
• Becker AM, Keck RW, Murtagh DS Jr, Becker AB, Hinman C, Selman SH. Prostatic involution after intraprostatic injection of cobra toxin. J Urol 2010;184:2192–6.
   PubMedGoogle Scholar